In a groundbreaking move in the field of biotechnology, Life Biosciences has initiated its first human trial, administering an experimental treatment aimed at reversing glaucoma by injecting it directly into the eye of a volunteer. This innovative approach seeks not just to mitigate vision loss associated with glaucoma but also to potentially regenerate healthy nerve cells in the eye. David Sinclair, co-founder and chairman of Life Biosciences, expresses optimism that if this treatment proves effective, similar methods could be developed to combat other age-related diseases, and maybe even reverse the aging process itself.
The concept behind this treatment revolves around the idea of ‘reprogramming’ cells back to a youthful state, a method gaining traction among various biotech firms focused on decelerating and potentially reversing aging. Aging is a multifaceted phenomenon, marked by numerous biological changes and challenges. Researchers have previously identified nine ‘hallmarks of aging,’ which include processes that contribute to age-related conditions. While some approaches, such as targeting telomere shortening or cellular senescence, have gained and lost popularity, the focus has now shifted to cellular reprogramming. This method leverages Nobel Prize-winning research that showed how four specific genetic factors can transform adult cells into stem cells, which can then develop into any other cell type.
The excitement surrounding reprogramming is underscored by substantial investments in the sector. Companies like Altos Labs, which was backed by prominent investors including Yuri Milner and Jeff Bezos with a funding of $3 billion, aim to harness this technology for rejuvenation purposes. Other companies like Retro Biosciences and NewLimit are also making strides in this area, with Retro seeking to extend human lifespan by a decade and NewLimit focusing on liver rejuvenation. Recently, Life Biosciences secured $80 million to further its research, including Sinclair’s ambitious plans for comprehensive body rejuvenation. While the potential of reprogramming is undeniable, it raises questions about efficacy and safety. As human trials commence and billions of dollars pour into research, the scientific community is poised at a pivotal moment, eager to see if a viable rejuvenation drug is on the horizon.
Source: Why “reprogramming” is the buzziest approach to reversing aging right now via MIT Technology Review